A-
Overall grade
B+
Financial quality
The sleeper story is operational leverage acceleration-NTRA just proved it can handle 1M+ quarterly units while maintaining 65% gross margins, a scale inflection that's getting lost in the headline MRD growth narrative. The obvious MRD story is real (249k units, Japan doubling TAM), but the binding constraint is no longer lab capacity or reimbursement-it's sales execution to penetrate the remaining 50% of oncologists who haven't tried Signatera. Steve's most revealing quote: 'We fired on all cylinders in Q1...nearly the most unit growth we have seen since I took over as CEO,' suggesting they're hitting an operational sweet spot. My view changes if Japan launch disappoints on ASPs or if the work-in-process ratio doesn't normalize by Q2, indicating underlying lab inefficiencies rather than volume-driven timing issues.
The 30-second version
- The real story is operational leverage hiding in plain sight
- MRD growth acceleration with 24k sequential adds, but Japan launch could double TAM overnight
- Work-in-progress ratio deterioration masks underlying margin strength
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $666M Q4 2025 (+40% YoY) | $697M Q1 2026 (+39% YoY) |
| Total Units Processed | 924k Q4 2025 | 1M+ Q1 2026 |
| Signatera Clinical Units | 225k Q4 2025 (+56% YoY) | 249k Q1 2026 (+55% YoY) |
| Signatera ASP | $1,225 Q4 2025 | $1,250 Q1 2026 |
| Gross Margin | 66.9% Q4 2025 (incl 3% true-ups) | 65% Q1 2026 |
| Organic Gross Margin | 63.7% Q4 2025 | ~67% Q1 2026 (normalized) |
| Women's Health Sequential Growth | Not disclosed Q4 | 63k units Q4-Q1 |
| Fetal Focus Run Rate | Launch in Q1 | ~200k annualized |
Accountability tracked
8 new promises made4 narrative shifts flagged6 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →